{"id":"nct:NCT02735707","kind":"trial","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","authors":["UMC Utrecht"],"author_count":1,"year":2016,"published":"2016-04-13","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT02735707","source_url":"https://clinicaltrials.gov/study/NCT02735707","archive_url":"https://space-kitty.com/papers/nct:NCT02735707","updated":"2024-07-12","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Community-acquired Pneumonia, Influenza, COVID-19"],"details":{"acronym":"REMAP-CAP","status":"RECRUITING","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":20000,"sponsor":"UMC Utrecht","conditions":["Community-acquired Pneumonia, Influenza, COVID-19"],"interventions":["DRUG: Ceftriaxone","DRUG: Moxifloxacin or Levofloxacin","DRUG: Piperacillin-tazobactam","DRUG: Ceftaroline","DRUG: Amoxicillin-clavulanate","DRUG: Standard course macrolide","DRUG: Extended course macrolide","OTHER: No systemic corticosteroid","DRUG: Fixed-duration Hydrocortisone","DRUG: Shock-dependent hydrocortisone"],"start_date":"2016-04-11","start_date_type":"ACTUAL","primary_completion_date":"2026-02-01","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"infectious-disease-amr","name":"Infectious Disease, Vaccines & Antimicrobial Resistance","domain_slug":"medicine"}],"cited_in_dossiers":[]}